Quality of life with the Bonebridge Transcutaneuos Bone-Conduction Implant in Adults and Children with Congenital Aural Atresia
23 April 2019 (online)
Since 2012 the the transcutaneous bone conduction hearing implant Bonebridge (BB, MedEl, Innsbruck, Austria) is used for patients with mixed or conductive hearing loss or single side deafness.
This study evaluates the quality of life with the BB in patients with congenital aural atresia. We used the Glasgow Benefit Inventory (GBI) for adults (29,95 y 12,4; n = 8) and for children (8,86 y 3,4; n = 13) the Glasgow Benefit Inventory for children (GBCI). We expanded the inventory by three more questions to get information about repeating the intervention, if they could decide again, about the daily usage und the unwillingly loss oft he audioprocessor (AP).
The Total Score shows significant improvement in the quality of life in both groups with a mean of 37,9 20,4 (GBI) and a mean of 24,03 19,8 (GCBI). The Social Support Score shows 50% (GBI) and 92,3% (GCBI) improvement. The additional questions show that 87,5% of the adolescents and 92,3% of the children would repeat the intervention. The daily usage > 9 hours/day in adolescents is 62,5% and in children 69,2%. The unwillingly and undisturbing loss of the AP is 87,5% and in the adult group, in the childrens group 53,8%. In 12,5% the loss is interfering in the adult group and 15,4% in the childrens group.